Despite lower forecast growth, the company's P/E ratio aligns with most firms, suggesting investors are less bearish than analysts. However, if the P/E aligns with the growth outlook, shareholders may face disappointment. The weak earnings outlook and slower growth suggest share price risk.

China Resources Boya Bio-pharmaceutical Group's stock price continues to drop despite healthier EPS and revenue growth, indicating a market readjustment of previous high expectations and possible influence of market uncertainties.